Treace Medical Concepts, Inc.

TMCI - Financial Snapshot

Metrics for TMCI

Price $1.86
Shares Outstanding 63.72M
All-Time Low $1.86
52-Week Low $1.82

Balance Statement Metrics

Net Cash / Share $0
cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding
Net Current Assets / Share $0.48
netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
Net Tangible Assets / Share $1.08
netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
Shares Outstanding Ave Change (Annual) 4.8%
Shares Δ YoY 0.99%
Avg CA Burn (Annual %) 8.92% (as of 2-20-2026)
Avg CA Burn (Quarterly %) -3.19% (as of 2-20-2026)

Earning Metrics

Max Earning Power / Share $-1.82
maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
Adjusted Earning Power $-2.43
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
Non-Cash Charges to Market Cap 2.08%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
Avg EBITDA (5Y) 0 (as of 2-20-2026)
Avg EBITDA (5Q) 610K (as of 2-20-2026)
Avg Net Income (5Y) -42.2M (as of 2-20-2026)
Avg Net Income (5Q) -13.1M (as of 2-20-2026)
Data as of: Price 02-27-26 16:00 ET, Balance Sheet 2025-09-30, Income Statement 2025-09-30, Cash Flow 2025-09-30

Indicators

Dividend indicators Value Date
Current Dividend Streak No 2-20-2026
Consecutive Years Paid No 2-20-2026
Pays Dividend No 2-20-2026
Income indicators Value Date
EBITDA Positive No 2-20-2026
Net Income Positive No 2-20-2026
Current Dividend Streak No 2-20-2026

Metric History Explorer

Pick a metric to view its history table and chart.

Tangible Book Value Per Share History

Formula: Tangible Book Value / shares from balance statements. Includes 5 quarterly + 4 annual.

Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).

Report Date Period TBV / Share Tangible Book Value Shares Used
2025-09-30 Quarterly $1.08 69M ($69,010,000) 63.7M (63,704,810)
2025-06-30 Quarterly $1.22 77.2M ($77,200,000) 63M (63,042,314)
2025-03-31 Quarterly $1.35 84.7M ($84,689,000) 62.9M (62,891,506)
2024-12-31 Quarterly $1.48 92M ($92,002,000) 62.4M (62,361,710)
2024-12-31 Annual $1.48 92M ($92,002,000) 62.4M (62,361,710)
2024-09-30 Quarterly $1.35 83.8M ($83,779,000) 62.3M (62,275,371)
2023-12-31 Annual $1.88 116.1M ($116,098,000) 61.7M (61,748,436)
2022-12-31 Annual $1.09 60.5M ($60,529,000) 55.6M (55,628,208)
2021-12-31 Annual $1.72 93.1M ($93,073,000) 54.2M (54,181,082)

Dividend Payments

Historical cash dividends per share from Yahoo ex-dividend dates.

Date Dividend / Share
No dividend payment history available yet

Shares Outstanding Changes

Date Shares Outstanding Delta
No recent share changes

Short Interest Changes

Latest short-interest change: 3,558,929 shares (7.34% of float) | Days to cover: 5.61

Date Short Interest Delta Δ %
2026-02-27 3,558,929 shares +315,417 +9.72%
2026-02-11 3,243,512 shares +235,919 +7.84%

Interesting Volume Days

Volume/ratio use shares outstanding as of the event date (frozen).

Date Volume Shares Outstanding Volume / Shares Price
No interesting volume events

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.